In this randomized , open-label , multicenter phase III study , patients were randomly assigned to receive SOX ( 80-120 mg/day S-1 for 2 weeks with 100 mg/m ( 2 ) oxaliplatin on day 1 , every 3 weeks ) or CS ( S-1 for 3 weeks with 60 mg/m ( 2 ) cisplatin on day 8 , every 5 weeks ) .